4.1 Review

Adherence to Antipsychotic Medication in Bipolar Disorder and Schizophrenic Patients A Systematic Review

期刊

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
卷 36, 期 4, 页码 355-371

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JCP.0000000000000523

关键词

adherence; antipsychotic; schizophrenia; bipolar disorder

资金

  1. Spanish Government
  2. FEDER [PI12/02077, PI11/01977, PI14/01900]
  3. Basque Foundation for Health Innovation and Research (BIOEF)
  4. Networking Center for Biomedical Research in Mental Health (CIBERSAM)
  5. University of the Basque Country [GIC12/84]
  6. Stanley Research Foundation [03-RC-003]
  7. Almirall
  8. AstraZeneca
  9. Bristol-Myers Squibb
  10. Cephalon
  11. Eli Lilly
  12. Glaxo-Smith-Kline
  13. Janssen-Cilag, Jazz
  14. Johnson Johnson
  15. Lundbeck
  16. Merck
  17. Otsuka
  18. Pfizer
  19. Sanofi-Aventis
  20. Servier
  21. Shering-Plough
  22. Solvay
  23. Spanish Ministry of Science and Innovation (CIBERSAM)
  24. Ministry of Science (Carlos III Institute)
  25. Basque Government
  26. Stanley Medical Research Institute
  27. Wyeth
  28. AB-Biotics
  29. Actavis
  30. Allergen
  31. Ferrer
  32. Forest Research Institute
  33. Gedeon Richter
  34. Janssen
  35. Roche
  36. Shire
  37. Sunovion
  38. Takeda
  39. Telefonica
  40. Brain and Behaviour Foundation
  41. Spanish Ministry of Economy and Competitiveness (CIBERSAM) [PI 12/00910]
  42. Seventh European Framework Programme (ENBREC)
  43. Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya [2014 SGR 398]
  44. Aequus
  45. Adamed
  46. Alexza
  47. Bial
  48. Dainippon Sumitomo Pharma
  49. Elan
  50. Eli Lily
  51. Gedeon Ritcher
  52. Novartis
  53. Organon
  54. Pierre-Fabre
  55. Qualigen
  56. Sumitomo Dainippon
  57. Telenofica
  58. Teva
  59. United Biosource Corporation

向作者/读者索取更多资源

Antipsychotics are the drugs prescribed to treat psychotic disorders; however, patients often fail to adhere to their treatment, and this has a severe negative effect on prognosis in these kinds of illnesses. Among the wide range of risk factors for treatment nonadherence, this systematic review covers those that are most important from the point of view of clinicians and patients and proposes guidelines for addressing them. Analyzing 38 studies conducted in a total of 51,796 patients, including patients with schizophrenia spectrum disorders and bipolar disorder, we found that younger age, substance abuse, poor insight, cognitive impairments, low level of education, minority ethnicity, poor therapeutic alliance, experience of barriers to care, high intensity of delusional symptoms and suspiciousness, and low socioeconomic status are the main risk factors for medication nonadherence in both types of disorder. In the future, prospective studies should be conducted on the use of personalized patient-tailored treatments, taking into account risk factors that may affect each individual, to assess the ability of such approaches to improve adherence and hence prognosis in these patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据